Silence Therapeutics plc (LON:SLN) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.00 and traded as low as $82.50. Silence Therapeutics shares last traded at $84.00, with a volume of 151,122 shares changing hands.
Separately, Peel Hunt reaffirmed a “buy” rating and issued a GBX 60 ($0.78) target price on shares of Renewi in a research report on Wednesday, July 3rd.
The firm has a market cap of $60.44 million and a P/E ratio of -3.20. The stock has a 50 day moving average price of GBX 62.58.
Silence Therapeutics Company Profile (LON:SLN)
Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs. It is developing various candidates for the treatment of cancer, iron overload disorders, cardiovascular disease, alcohol use disorder, and other metabolic diseases.
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.